AHT-102, a novel Fab-like bispecific antibody, achieves an optimized therapeutic balance through its low-affinity CD3 arm and Fc-free format. It demonstrates significant anti-tumor efficacy and exceptional targeting specificity while avoiding systemic immunotoxicity typically associated with CD3-targeting agents. These findings provide a robust scientific rationale for the clinical translation of AHT-102 in patients with CLDN18.2-positive cancers.
Building similarity graph...
Analyzing shared references across papers
Loading...
Huilun Chu
Guili Xu
Yunlong Liu
Drugs in R&D
Beijing Proteome Research Center
Wuhan Institute of Bioengineering
Tianjin Research Institute of Electric Science (China)
Building similarity graph...
Analyzing shared references across papers
Loading...
Chu et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69a287b00a974eb0d3c03903 — DOI: https://doi.org/10.1007/s40268-026-00535-y